No profile data available.
Charles River Laboratories International, Inc. (CRL) is a healthcare company in the early-stage drug development research industry, based in Wilmington, United States, with about 18,300 full-time employees.
It reported revenue of $4.02 billion for fiscal year 2025, down 0.9% from fiscal year 2024, and net income of -$144.34 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.00 billion, down 2.7% from a year before. Its largest business segment, Discovery and Safety Assessment, brought in 60% of segment revenue in fiscal year 2025; United States was the largest region with 53%. Its market capitalization was $14.41 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Charles River Laboratories International reported $4.02 billion in revenue for fiscal year 2025, down 0.9% from $4.05 billion in fiscal year 2024. In Q2 2026 revenue was $1.00 billion.
Discovery and Safety Assessment, with $2.40 billion or 60% of segment revenue in fiscal year 2025. Next: Research Models and Services (21%) and Manufacturing Solutions (19%).
United States: 53% of revenue by region in fiscal year 2025, followed by Europe (27%).
$14.41 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (early-stage drug development research) include Champions Oncology, Inc. (CSBR), Bioqual, Inc. (BIOQ).